FDA Afrezza Approval: MannKind at 65% by May 29

Two days remain before this market closes, and the FDA’s decision on MannKind’s Afrezza inhaled insulin sits at 64.5% probability for approval. That’s a majority lean, but not a confident one. Afrezza already holds FDA approval for diabetes management, so the market question here turns on whether a specific supplemental or label-expansion decision clears the agency’s bar before May 29.

The market question asks whether the FDA approves MannKind’s Afrezza. YES trades at $0.65 and NO at $0.36, with the contract resolving May 29, 2026. Total volume stands at $1,101, which is thin by any measure. At $331 in 24-hour trading, this market reflects a handful of traders rather than broad conviction.

How the Afrezza FDA Approval Contract Works

YES pays out if the FDA issues an approval decision for MannKind’s Afrezza before or on the resolution date of May 29, 2026. NO pays out if that approval does not arrive by the deadline. The FDA is the sole resolving authority here. No Congressional action or court ruling substitutes.

• YES is priced at $0.65, implying a 64.5% probability of FDA approval by May 29.
• NO is priced at $0.36, implying a 35.5% probability that approval does not arrive in time.

The NO side wins on silence or delay. The FDA approves nothing by default. If MannKind’s application is still under review, if a Complete Response Letter arrives, or if the agency requests additional data, the deadline passes and NO pays. A 35.5% probability on NO means roughly one-in-three traders expect exactly that outcome.

Sponsored Partner

Momentum and Market Signals Show Thin Conviction

The momentum signal here is essentially flat. The 1-hour price change registers zero movement, and no 24-hour change data is available. The trend score of 27.26 sits in subdued territory, well below levels that would signal active repositioning. Nothing in the price action suggests traders have received new information in the past day.

Total volume at $1,101 and 24-hour volume at $331 puts this firmly in the low-conviction category. Liquidity sits at $1,797. These are thin order books. A single meaningful trade, even a few hundred dollars, can move this price sharply before the May 29 close. Thin liquidity means price can move sharply on new data, and two days remain for exactly that to happen.

• The momentum composite shows no directional signal in the past hour, consistent with a market in a holding pattern ahead of a binary catalyst.
• Total volume of $1,101 indicates this contract has attracted limited trader interest relative to larger FDA-related markets.
• Liquidity at $1,797 is enough to absorb small trades but not institutional-sized positions.
• The 1-hour price change of 0.0% and a subdued trend score of 27.26 point to a market waiting, not moving.
• Related markets show the FDA approval space has a wide range: Retatrutide sits at 23%, Daraxonrasib at 61%, and Cingulate’s CTX-1301 at 37%, placing Afrezza in the upper tier of current FDA market pricing.

Lines Analysis: MannKind, the FDA Calendar, and What Moves This Market

Here’s what the measurements are telling us: Afrezza has been FDA-approved since 2014 for adults with type 1 and type 2 diabetes. Any current market question about FDA approval implies a supplemental NDA, a label change, a new indication, or a manufacturing site approval. MannKind has been pursuing expanded use cases for Afrezza, including a pediatric indication and potential for automated insulin delivery integration. If the FDA’s Prescription Drug User Fee Act (PDUFA) target action date falls on or before May 29, the YES side is well-positioned. If that date is later or unknown, the market is pricing possibility rather than scheduled certainty.

The data doesn’t care about the politics, but it does care about calendars. A 35.5% NO probability is not trivial. FDA supplemental approvals can slip. Complete Response Letters arrive without public warning. MannKind is a smaller biopharmaceutical company with limited resources to absorb a CRL and resubmit before a hard market deadline. That structural vulnerability keeps NO viable. The FDA does not negotiate deadlines with prediction markets.

• A confirmed PDUFA date on or before May 29 would push YES toward 80% or higher, as the FDA meets its target action dates the majority of the time.
• Any FDA advisory committee meeting scheduled before May 29 would signal active review and likely lift YES pricing.
• A Complete Response Letter from the FDA arriving before May 29 would immediately reprice NO toward 90%+.
• MannKind’s investor communications and any SEC filings in the next 48 hours would be the fastest signal available to traders.
• Related market pricing, especially the 61% on Daraxonrasib, suggests the broader FDA approval space is not in a particularly favorable environment right now.

The market is pricing uncertainty, not science. With $1,101 in total volume, this contract reflects informed speculation by a small group of traders rather than a deep information market. The data favors YES at 64.5%, but the thin liquidity and two-day window mean any official FDA communication shifts the equilibrium immediately.

LEAN YES, LOW CONVICTION

The 64.5% YES price reflects a plausible path to approval but lacks the volume and catalysts to call this settled. Thin liquidity and a 48-hour window make this market highly reactive to any official FDA communication.

What the market says: At 64.5%, traders assign Afrezza a moderate majority chance of FDA approval by May 29. With only $1,101 in total volume and resolution two days away, this probability can reprice dramatically on a single piece of regulatory news.

Key unknown: The single most important data point is whether MannKind has a confirmed PDUFA target action date on or before May 29, 2026. That one calendar entry determines whether YES is a scheduled outcome or a speculative bet.